Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 13/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 8/20 | 1.00 |
| ▸ | TUBB | P07437 | 8/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 8/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 8/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 8/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 8/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 8/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 8/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 8/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 8/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 8/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 8/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 8/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 8/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.70 |
| ▸ | APP | P05067 | 1/20 | 0.70 |
| ▸ | NQO2 | P16083 | 1/20 | 0.70 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.66 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291905 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29501731 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2144727 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29611250 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL29351804 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL6842159 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL6842165 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10000736 | 0.91 | TUBB1 (0.82) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL23671610 | 0.88 | TUBB1 (0.78) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL23671597 | 0.88 | TUBB1 (0.78) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | claimed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | claimed |
| EP-2331093-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | The Trustees of Columbia University in the City of New York (US) | 2011-06-15 | — | — | EP | claimed |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-05-26 | — | — | US | claimed |
| WO-2010025272-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-03-04 | — | — | WO | claimed |
| WO-2009105123-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-08-27 | — | — | WO | claimed |
| WO-2008103916-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) | 2008-08-28 | — | — | WO | claimed |
| EP-1405843-B1 | METHOD FOR PRODUCING AMINOSTILBENE DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-20 | — | — | EP | claimed |
| US-7087627-B1 | Combinations for the treatment of diseases involving angiogenesis | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-08-08 | — | — | US | claimed |
| US-6930205-B2 | Process for preparing aminostilbene derivatives | AJINOMOTO CO., INC. (JP) | 2005-08-16 | — | — | US | claimed |
| US-20040176642-A1 | Process for preparing aminostilbene derivatives | AJINOMOTO CO. INC (JP) | 2004-09-09 | — | — | US | claimed |
| EP-1405843-A1 | METHOD FOR PRODUCING AMINOSTILBENE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2004-04-07 | — | — | EP | claimed |
| JP-8301831-A | — | — | None | — | — | JP | disclosed |
| JP-7228558-A | — | — | None | — | — | JP | disclosed |
| CN-120091971-A | Carbon nanotube dispersion, method for preparing the same, electrode slurry composition comprising the same, electrode comprising the same, and lithium secondary battery comprising the same | 贝特瑞尔有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-120091972-A | Carbon nanotube dispersion, method for preparing the same, electrode slurry composition comprising the same, electrode comprising the same, and lithium secondary battery comprising the same | 贝特瑞尔有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-0731085-A1 | Stilbene derivatives and pharmaceutical compositions containing them | Ajinomoto Co., Inc. (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5525632-A | ANTICARCINOGENIC AGENTS | AJINOMOTO CO., LTD. (JP) | 1996-06-11 | — | — | US | disclosed |
| JP-H07228558-A | STILBENE DERIVATIVE AND CARCINOSTATIC AGENT CONTAINING THE SAME | AJINOMOTO CO INC | 1995-08-29 | — | — | JP | disclosed |
| EP-0641767-A1 | Cytotoxic stilbene derivatives and pharmaceutical composition containing them | Ajinomoto Co., Inc. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176642-A1 | Process for preparing aminostilbene derivatives | DHPS, AASDHPPT, NPEPPS | TUBB1 697/4885TUBB4A 1312/4885TUBB 945/4885 |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | TUBA1C, TUBB1, TOP1 | TUBB1 2/4885TUBB4A 20/4885TUBB 7/4885 |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | BDNF, NGF, NTRK2 | TUBB1 7/4885TUBB4A 19/4885TUBB 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.